Study to assess the pharmacokinetics and safety of WAL2014 capsules administered orally as a multiple dose to healthy adult male volunteers in double blind manner.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Maximum concentration of the analyte in plasma (Cmax)
Time frame: up to day 14
Time to reach maximum plasma concentration (tmax)
Time frame: up to day 14
Area under the plasma concentration-time curve (AUC)
Time frame: up to day 14
Urinary excretion rate
Time frame: up to day 14
Minimum plasma concentration (Cmin)
Time frame: up to day 14
Mean residence time (MRT)
Time frame: up to day 14
Terminal half-life (t1/2)
Time frame: up to day 14
Distribution volume
Time frame: up to day 14
Total clearance
Time frame: up to day 14
Number of subjects with adverse events
Time frame: up to 22 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.